Intellia Therapeutics, Inc.
NTLA
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alā¦ read more
Healthcare
Biotechnology
8 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$18.96
Price+9.80%
$1.69
1Y
Price
Market Cap
$2.036b
Mid
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financials Overview
Key metrics over the past few years-385.3%
EBITDA Margin-371.3%
Net Profit Margin-425.7%
Free Cash Flow MarginRevenue
$52.857m
+45.0%
1y CAGR+24.1%
3y CAGR+7.3%
5y CAGREarnings
-$480.194m
-0.9%
1y CAGR-29.3%
3y CAGR-48.7%
5y CAGREPS
-$4.69
+1.1%
1y CAGR-19.3%
3y CAGR-30.3%
5y CAGRBook Value
$715.255m
$898.894m
Assets$183.639m
Liabilities$102.591m
DebtDebt to Assets
11.4%
-0.2x
Debt to EBITDAFree Cash Flow
-$421.818m
-2.4%
1y CAGR-23.8%
3y CAGR-104.0%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company